

# **QUALITY ASSESSMENT FOR COMPLETE BLOOD PICTURE PERFORMANCE**

**Thesis**

Submitted for Partial Fulfillment of Master Degree in Clinical  
and Chemical Pathology

**By**

**Maysa Elazab Solyman Ahmed**

M.B.B.Ch, Faculty of Medicine, Mansoura University

**SUPERVISED BY**

***Professor. Iman Mohamed Amin Omar***

Professor of Clinical and Chemical Pathology  
Faculty of Medicine  
Ain Shams University

***Professor. Dina Adel Fouad Mohamed***

Professor of Clinical and Chemical Pathology  
Faculty of Medicine  
Ain Shams University

Faculty of Medicine  
Ain Shams University  
2012



﴿ قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا

إِلَّا مَا عَلَّمْتَنَا إِنَّكَ

أَنْتَ الْعَلِيمُ الْحَكِيمُ ﴾

صدق الله العظيم

# Acknowledgement

*First of all, thanks to **ALLAH** who granted me the ability to accomplish this work.*

*It has been a great honor and extreme pleasure for me to perform this study under the supervision of Prof. Dr. Iman Mohamed Amin Omar, Professor of Clinical Pathology, Faculty of medicine, Ain Shams University for her meticulous supervision and guidance, I am extremely gratefull.*

*I would like to express my deepest and utmost thanks to Prof. Dr. Dina Adel Fouad Mohamed, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her sincere guidance and great help. I was honored to be her candidate and to be guided all through this work by her kind and valuable advice.*

# TABLE OF CONTENT

<b>List of Abbreviations</b> .....	<b>I</b>
<b>List of Tables</b> .....	<b>IV</b>
<b>List of Figures</b> .....	<b>IX</b>
<b>Introduction</b> .....	<b>1</b>
<b>Aim of the work</b> .....	<b>6</b>
<b>Chapter 1: ISO 15189 Requirements</b> .....	<b>7</b>
1. Scope .....	9
2. Normative references .....	10
3. Terms and definitions .....	11
4. Management requirement .....	15
5. Technical requirements .....	24
<b>Chapter 2: Internal Quality Control and Evaluation of Automated Hematology Analyzers</b> .....	<b>33</b>
▪ Pre-Analytical phase .....	34
▪ Analytical phase .....	39
▪ Post-analytical phase .....	50

<b>Chapter 3: External quality assessment</b> .....	<b>53</b>
▪ Physical Inspection .....	56
▪ Pattern Analysis .....	57
▪ Survey methods done by proficiency testing .....	59
<b>Materials and Methods</b> .....	<b>73</b>
<b>Results</b> .....	<b>95</b>
<b>Discussion</b> .....	<b>175</b>
<b>Summary and Conclusion</b> .....	<b>191</b>
<b>Recommendations</b> .....	<b>197</b>
<b>References</b> .....	<b>199</b>
<b>Arabic summary</b>	

## LIST OF ABBREVIATIONS

<b>A2LA</b>	The American Association for Laboratory Accreditation
<b>AHAs</b>	Automated Hematology Analyzers
<b>B</b>	Bias
<b>CAP</b>	College of American Pathologists
<b>CBC</b>	Complete Blood Count
<b>CLIA</b>	Clinical Laboratory Improvement Amendment
<b>CV</b>	Coefficient of Variation
<b>CV<sub>g</sub></b>	between-subject biologic variation
<b>CV<sub>w</sub></b>	within-subject biologic variation
<b>%Dev</b>	percentage deviation
<b>EDTA</b>	Ethylene Diamine Tetraacetic Acid
<b>EQA</b>	external Quality Assessment
<b>EQAS</b>	External Quality Assurance programs
<b>EQC</b>	External Quality Control
<b>Hb</b>	Haemoglobin
<b>Hct</b>	Haematocrit
<b>I</b>	Imprecision
<b>IEC</b>	International Electrotechnical Commission
<b>IQC</b>	Internal Quality Control

<b>ISO</b>	International Organization for Standardization
<b>KPI</b>	key performance indicators
<b>K2-EDTA</b>	dipotassium Ethylene Diamine Tetraacetic Acid
<b>K3-EDTA</b>	tri-potassium Ethylene Diamine Tetraacetic Acid
<b>MCH</b>	Mean Corpuscular Haemoglobin
<b>MCHC</b>	Mean Corpuscular Hemoglobin Concentration
<b>MCV</b>	Mean Corpuscular Volume
<b>MPV</b>	Mean Platelet Volume
<b>NCCLS</b>	National Committee for Clinical Laboratory Standards
<b>PCV</b>	Packed Cell Volume
<b>PLT</b>	Platelets
<b>PMN</b>	Polymorphonuclear leukocytes
<b>PT</b>	Proficiency Testing
<b>QC</b>	Quality Control
<b>QMS</b>	Quality Management System
<b>RBC</b>	red blood cell
<b>RDW</b>	Red cell Distribution Width
<b>RIQAS</b>	Randox International Quality Assessment Scheme
<b>RM%Dev</b>	Running Mean Percentage Deviation
<b>RMSDI</b>	Running Mean Standard Deviation Index

<b>RMETS</b>	Running Mean Target Score
<b>SD</b>	Standard Deviation
<b>SDI</b>	Standard Deviation Index
<b>SPSS</b>	Statistical Package for the Social Sciences
<b>TV</b>	Target Value
<b>TAT</b>	Turnaround Time
<b>TDPA</b>	Target Deviation for Performance Assessment
<b>TE</b>	Total Error
<b>TEa</b>	Total allowable Errors
<b>TLC</b>	Total Leukocyte Count
<b>TLE</b>	Total Lab Error
<b>TS</b>	Target Score
<b>WBC</b>	white blood cell
<b>WHO</b>	world health organization



# LIST OF TABLES

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
<b>Table 1:</b>	Some pre-analytical sources of errors in blood counts .....	36
<b>Table 2:</b>	Some analytical sources of errors in blood counts .....	40
<b>Table 3:</b>	Some post-analytical sources of errors in blood counts .....	50
<b>Table 4:</b>	Situations leading to erroneous results on automated haematology analyzers .....	50
<b>Table 5:</b>	Desirable Specifications for Total Error, Imprecision, and Bias, derived from intra- and inter-individual biologic variation .....	62
<b>Table 6:</b>	CLIA Proficiency Testing criteria for acceptable analytical performance .....	64
<b>Table 7:</b>	Benefits of EQA programs .....	72
<b>Table 8:</b>	LH750 IQC measurements from Feb to March 2012 .....	97
<b>Table 9:</b>	(EQC) Analysis of Hb for LH750 cycle 34 .....	105
<b>Table 10:</b>	(EQC) Analysis of HCT for LH750 cycle 34 ...	106
<b>Table 11:</b>	(EQC) Analysis of MCH for LH750 cycle 34 ...	107
<b>Table 12:</b>	(EQC) Analysis of MCHC for LH750 cycle 34..	108
<b>Table 13:</b>	(EQC) Analysis of MCV for LH750 cycle 34...	109
<b>Table 14:</b>	(EQC) Analysis of MPV for LH750 cycle 34 ...	110
<b>Table 15:</b>	(EQC) Analysis of PLT for LH750 cycle 34 ....	111
<b>Table 16:</b>	(EQC) Analysis of RBC for LH750 cycle 34 ...	112
<b>Table 17:</b>	(EQC) Analysis of RDW for LH750 cycle 34 ...	113
<b>Table 18:</b>	(EQC) Analysis of TLC for LH750 cycle 34 ...	114
<b>Table 19:</b>	End cycle 34 conclusion LH 750 .....	115

<b>Table 20:</b> LH750 RIQAS summary page cycle 34 sample 7 .....	116
<b>Table 21:</b> LH750 RIQAS summary page cycle 34 sample 8 .....	116
<b>Table 22:</b> LH750 RIQAS summary page cycle 34 sample 9 .....	117
<b>Table 23:</b> LH750 RIQAS summary page cycle 34 sample 10 .....	117
<b>Table 24:</b> LH750 RIQAS summary page cycle 34 sample 11 .....	118
<b>Table 25:</b> LH750 RIQAS summary page cycle 34 sample 12 .....	118
<b>Table 26:</b> (EQC) Analysis of Hb for LH750 cycle 35 ...	120
<b>Table 27:</b> (EQC) Analysis of HCT for LH750 cycle 35 ...	121
<b>Table 28:</b> (EQC) Analysis of MCH for LH750 cycle 35 ..	122
<b>Table 29:</b> (EQC) Analysis of MCHC for LH750 cycle 35.	123
<b>Table 30:</b> (EQC) Analysis of MCV for LH750 cycle 35...	124
<b>Table 31:</b> (EQC) Analysis of MPV for LH750 cycle 35...	125
<b>Table 32:</b> (EQC) Analysis of PLT for LH750 cycle 35 ....	126
<b>Table 33:</b> (EQC) Analysis of RBC for LH750 cycle 35 ...	127
<b>Table 34:</b> (EQC) Analysis of RDW for LH750 cycle 35...	128
<b>Table 35:</b> (EQC) Analysis of TLC for LH750 cycle 35 ...	129
<b>Table 36:</b> End cycle 35 conclusion LH 750 .....	130
<b>Table 37:</b> LH750 RIQAS summary page cycle 35 sample 1 .....	131
<b>Table 38:</b> LH750 RIQAS summary page cycle 35 sample 2 .....	131
<b>Table 39:</b> LH750 RIQAS summary page cycle 35 sample 3 .....	132
<b>Table 40:</b> LH750 RIQAS summary page cycle 35 sample 4 .....	132
<b>Table 41:</b> LH750 RIQAS summary page cycle 35 sample 5 .....	133

<b>Table 42:</b> LH750 RIQAS summary page cycle 35 sample 6 .....	133
<b>Table 43:</b> LH750 RIQAS summary page cycle 35 sample 7 .....	134
<b>Table 44:</b> LH750 RIQAS summary page cycle 35 sample 8 .....	134
<b>Table 45:</b> LH750 RIQAS summary page cycle 35 sample 9 .....	135
<b>Table 46:</b> LH750 RIQAS summary page cycle 35 sample 10 .....	135
<b>Table 47:</b> GEN-S IQC measurements from Feb to March 2012 .....	137
<b>Table 48:</b> (EQC) Analysis of HB for GEN-S cycle 34 .....	143
<b>Table 49:</b> (EQC) Analysis of HCT for GEN-S cycle 34....	144
<b>Table 50:</b> (EQC) Analysis of MCH for GEN-S cycle 34...	145
<b>Table 51:</b> (EQC) Analysis of MCHC for GEN-S cycle 34.	146
<b>Table 52:</b> (EQC) Analysis of MCV for GEN-S cycle 34...	147
<b>Table 53:</b> (EQC) Analysis of MPV for GEN-S cycle 34...	148
<b>Table 54:</b> (EQC) Analysis of PLT for GEN-S cycle 34 ...	149
<b>Table 55:</b> (EQC) Analysis of RBC for GEN-S cycle 34...	150
<b>Table 56:</b> (EQC) Analysis of RDW for GEN-S cycle 34...	151
<b>Table 57:</b> (EQC) Analysis of TLC for GEN-S cycle 34 ...	152
<b>Table 58:</b> End cycle 34 conclusion GEN-S .....	153
<b>Table 59:</b> GEN-S RIQAS summary page cycle 34 sample 7 .....	154
<b>Table 60:</b> GEN-S RIQAS summary page cycle 34 sample 8 .....	154
<b>Table 61:</b> GEN-S RIQAS summary page cycle 34 sample 9 .....	155
<b>Table 62:</b> GEN-S RIQAS summary page cycle 34 sample 10 .....	155
<b>Table 63:</b> GEN-S RIQAS summary page cycle 34 sample 11 .....	156
<b>Table 64:</b> GEN-S RIQAS summary page cycle 34	156

sample 12 .....	158
<b>Table 65:</b> (EQC) Analysis of HB for GEN-S cycle 35 .....	158
<b>Table 66:</b> (EQC) Analysis of HCT for GEN-S cycle 35 ...	159
<b>Table 67:</b> (EQC) Analysis of MCH for GEN-S cycle 35...	160
<b>Table 68 :</b> (EQC) Analysis of MCHC for GEN-S cycle 35.	161
<b>Table 69:</b> (EQC) Analysis of MCV for GEN-S cycle 35...	162
<b>Table 70:</b> (EQC) Analysis of MPV for GEN-S cycle 35...	163
<b>Table 71:</b> (EQC) Analysis of PLT for GEN-S cycle 35 ...	164
<b>Table 72:</b> (EQC) Analysis of RBC for GEN-S cycle 35...	165
<b>Table 73:</b> (EQC) Analysis of RDW for GEN-S cycle 35...	166
<b>Table 74:</b> (EQC) Analysis of TLC for GEN-S cycle 35 ...	167
<b>Table 75:</b> End cycle 35 conclusion GEN-S .....	168
<b>Table 76:</b> GEN-S RIQAS summary page cycle 35	
sample 1 .....	169
<b>Table 77:</b> GEN-S RIQAS summary page cycle 35	
sample 2 .....	169
<b>Table 78:</b> GEN-S RIQAS summary page cycle 35	
sample 3 .....	170
<b>Table 79:</b> GEN-S RIQAS summary page cycle 35	
sample 4 .....	170
<b>Table 80:</b> GEN-S RIQAS summary page cycle 35	
sample 5 .....	171
<b>Table 81:</b> GEN-S RIQAS summary page cycle 35	
sample 6 .....	171
<b>Table 82:</b> GEN-S RIQAS summary page cycle 35	
sample 7 .....	172
<b>Table 83:</b> GEN-S RIQAS summary page cycle 35	
sample 8 .....	172
<b>Table 84:</b> GEN-S RIQAS summary page cycle 35	
sample 9 .....	173
<b>Table 85:</b> GEN-S RIQAS summary page cycle 35	
sample 10 .....	173
<b>Table 86:</b> Target score mean for all studied parameters analyzed by LH 750 and GEN-S in cycle 34	174

## LIST OF FIGURES

<i>Fig No.</i>	<i>Title</i>	<i>Page</i>
<b>Fig1:</b>	Schewart/levey-jenning chart over one month ....	46
<b>Fig2:</b>	1 <sub>3S</sub> Reject when a single control measurement exceeds the mean plus 3s or the mean minus 3s control limit. (Random error) .....	47
<b>Fig3:</b>	1 <sub>2S</sub> The mean plus/minus 2s. In the original Westgard multirule QC procedure, this rule is used as a warning rule. (Random error) .....	47
<b>Fig4:</b>	2 <sub>2S</sub> Reject when 2 consecutive control measurements exceed the same mean plus 2s or the same mean minus 2s control limit. (Systematic error) .....	48
<b>Fig5:</b>	R <sub>4S</sub> Reject when 1 control measurement in a group exceeds the mean plus 2s and another exceeds the mean minus 2s. (Random error) .....	48
<b>Fig6:</b>	4 <sub>1S</sub> Reject when 4 consecutive control measurements exceed the same mean plus 1s Or the same mean minus 1s control limit. (Systematic error) .....	49
<b>Fig7:</b>	10 <sub>X</sub> Reject when 10 consecutive control measurements fall on one side of the mean. (Systematic error) .....	49
<b>Fig8:</b>	EQC analysis of Haemoglobin by Coulter LH700...	68
<b>Fig9:</b>	Histogram of laboratory result for hemoglobin g/dl .....	69

<b>Fig10:</b> Summary of all methods (instruments) involved in interlaboratory comparison by EQCA .....	69
<b>Fig11:</b> Report Summary page as supplied by RIQAS.....	70
<b>Fig12:</b> Example of EQC materials which are supplied in set of 12 numbered samples, processed in a certain date according to the instructions of EQC programme .....	73
<b>Fig13:</b> Coulter Method of Counting and Sizing .....	78
<b>Fig14:</b> Principles of automated hematology analyzers .....	80
<b>Fig15:</b> LH750 Hematology Analyzer .....	86
<b>Fig16:</b> GEN-S Hematology Analyzer .....	86
<b>Fig17:</b> Report text section .....	89
<b>Fig18:</b> LH750 IQC chart for WBC,RBC and HGB .....	98
<b>Fig19:</b> LH750 IQC charts for HCT, MCV and MCH .....	99
<b>Fig20:</b> LH750 IQC charts for MCH, RDW and PLT.....	100
<b>Fig21:</b> LH750 IQC chart for MPV .....	101
<b>Fig22:</b> GEN-S IQC charts for WBC, RBC and HGB.....	138
<b>Fig23:</b> GEN-S IQC charts for HCT, MCV and MCH.....	139
<b>Fig24:</b> GEN-S IQC charts for MCHC, RDW and PLT .....	140
<b>Fig25:</b> GEN-S IQC chart for MPV .....	141

## **INTRODUCTION**

Proficiency testing (PT) is a type of inter-laboratory comparison exercise in which samples are circulated to the participating laboratories; results are then collected and evaluated centrally. Each laboratory is then informed of its performance relative to the other laboratories in the scheme and relative to either true or consensus result for the sample. Performance is usually quoted in terms of standard deviations and is defined as a method of checking lab performance by means of inter-laboratory comparison achieved value and the consensus or true value. In some schemes participants are given a pass /fail rating. (*Ramirez et al. ,1992*).

Proficiency testing provides a challenge to laboratory's routine methods and procedures. It also provides feedback to laboratories as to whether they are performing their work in accordance with international criteria for technical competence. A laboratory's participation in proficiency testing activities is a requirement of the accreditation ISO 15189 according to international standards.

([www.a2la.org/.../15189\\_General\\_Requirements](http://www.a2la.org/.../15189_General_Requirements), 2007).